Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
| ▸ | TLR2 | O60603 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | RRM1 | P23921 | 1/20 | 0.52 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | KDM4A | O75164 | 1/20 | 0.50 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.50 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.50 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8615285 | 0.99 | DPP7 (0.59) | DPP7POLBKCNH2TLR2CYP2C9 | |
| SCHEMBL10626773 | 0.93 | DPP7 (0.63) | DPP7CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL10626768 | 0.93 | DPP7 (0.63) | DPP7CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL14444028 | 0.86 | POLB (0.55) | POLBKCNH2CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL30889119 | 0.86 | MMP2 (0.67) | POLBTLR2CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL7272130 | 0.85 | SPHK1 (0.61) | DPP7POLBTLR2CTSKKMT2A | |
| SCHEMBL20366256 | 0.85 | MMP2 (0.55) | DPP7POLBKCNH2CYP2C9CYP2C19 | |
| SCHEMBL13073492 | 0.85 | POLB (0.66) | POLBCYP2C9CYP2C19CYP2D6KMT2A | |
| SCHEMBL13073332 | 0.85 | POLB (0.66) | POLBCYP2C9CYP2C19CYP2D6KMT2A | |
| SCHEMBL5322284 | 0.83 | POLB (0.59) | POLBCYP2C9CYP2C19CYP1A2CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170233443-A1 | CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE | NOVARTIS AG (CH) | 2017-08-17 | — | — | US | disclosed |
| US-9683019-B2 | Cyclic polypeptides for the treatment of heart failure | NOVARTIS AG (CH) | 2017-06-20 | — | — | US | disclosed |
| US-20160108091-A1 | CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
| US-9266925-B2 | Cyclic polypeptides for the treatment of heart failure | NOVARTIS AG (CH) | 2016-02-23 | — | — | US | disclosed |
| US-20150031604-A1 | CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE | NOVARTIS AG (CH) | 2015-01-29 | — | — | US | disclosed |
| EP-0838471-A1 | PEPTIDE DERIVATIVES AND ANGIOTENSIN IV RECEPTOR AGONIST | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1998-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031604-A1 | CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE | NPY1R, ACKR3, IAPP | DPP7 1563/4885POLB 1730/4885KCNH2 674/4885 |
| US-20170233443-A1 | CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE | NPY1R, ACKR3, IAPP | DPP7 1563/4885POLB 1730/4885KCNH2 674/4885 |
| US-20160108091-A1 | CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE | NPY1R, ACKR3, IAPP | DPP7 1563/4885POLB 1730/4885KCNH2 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.